RE: Not sure if this link has been posted before12 Apr 2023 12:43
Also, they do rhyme with discussions we have here of what we see as issues with scancell... The Lindy IP one I don't really worry too much about she has used Scancell as the vechile to progress her full IP which is why she brought the GlyMaBs and Avidimab inhouse and why I think now moditope is showing the effectiveness Zacakri holdings is no longer needed as back up... But the first part I think we can all nod in agreement with... really very science focused but have been less so when it comes to commercial nous
'd) The current management’s focus is too involved with the science. In our view, we see a situation
evolving wherein the multiple early- stage assets (whilst excellent from a de-risking perspective)
could create a ‘problem of plenty’. The company’s management team needs to be strengthened
with members from a commercial background, who can provide sufficient analytics and decision
support so that management can sequence the assets better. A better sequencing of assets
would result in lower equity dilution as funds are utilised to take 1 or 2 assets to later stages –
which can then be partnered out or sold at higher valuations
e) The second company specific risk in our view is that of key person risk – Scancell is still an early
clinical stage company, and there is key person risk with Professor Lindy Durrant chairing the
dual roles of Chief Executive Officer and Chief Science Officer. The company’s patents and
intellectual property is built upon and around her work. If she were to become unavailable, due
to unforeseen circumstances, it could impact the company’s prospects and might make it
difficult to secure future funding.'